Adial Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Co.'s lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. We show 3 historical shares outstanding datapoints in our coverage of ADIL's shares outstanding history.
Understanding the changing numbers of ADIL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADIL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADIL by allowing them to research ADIL shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
